title: Impact of fatigue in multiple sclerosis: the Fatigue Impact Scale for Daily Use (D-FIS).
abstract: OBJECTIVE
  The Fatigue Impact Scale for Daily Use (D-FIS) is an eight-item instrument designed to measure subjective daily experience of fatigue. This study sought to determine the metric properties of the D-FIS in multiple sclerosis (MS) patients.
  
  
  METHODS
  Sixty-eight patients with operationally-defined MS and fatigue (54.8% of the sample) underwent the D-FIS. Usual clinical measures for MS, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Functional Assessment of Multiple Sclerosis (FAMS) were also applied. In addition, patients with fatigue completed the Fatigue Descriptive Scale, the Multidimensional Fatigue Inventory (MFI), a Visual Analogue Scale for Fatigue (VAS-F), and a Global Perception of Fatigue Scale (GPF).
  
  
  RESULTS
  Full computable data, 95.6%; both floor and ceiling effect=1.54%; item-total correlation=0.62 (item 1) to 0.84 (item 6); Cronbach's alpha=0.91; item homogeneity =0.55; standard error of measurement=3.18; convergent validity with other fatigue measures=-0.57 (VAS-F); 0.52 (GPF); and 0.46 (MFI-general fatigue). Test-retest reliability (ICC)=0.81. There was a strong association between health-related quality of life (HRQoL) (FAMS) and D-FIS (rS=0.70).
  
  
  CONCLUSIONS
  In this study, D-FIS proved to be a feasible and valid instrument for measuring MSrelated fatigue, a frequent symptom associated with deterioration of patients' HRQoL.
authors.affiliation: Department of Neurology, Móstoles General Hospital, and Gregorio Marañón University, Madrid, Spain. jbenitol@meditex.es
authors.forename: J
authors.initials: J
authors.lastname: Benito-León
authors.forename: P
authors.initials: P
authors.lastname: Martínez-Martín
authors.forename: B
authors.initials: B
authors.lastname: Frades
authors.forename: M L
authors.initials: ML
authors.lastname: Martínez-Ginés
authors.forename: C
authors.initials: C
authors.lastname: de Andrés
authors.forename: J E
authors.initials: JE
authors.lastname: Meca-Lallana
authors.forename: A R
authors.initials: AR
authors.lastname: Antigüedad
authors.forename: B
authors.initials: B
authors.lastname: Huete-Antón
authors.forename: E
authors.initials: E
authors.lastname: Rodríguez-García
authors.forename: J
authors.initials: J
authors.lastname: Ruiz-Martínez
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000547:Amantadine / Q000627:therapeutic use; D001559:Benzhydryl Compounds / Q000627:therapeutic use; D000697:Central Nervous System Stimulants / Q000627:therapeutic use; D015259:Dopamine Agents / Q000627:therapeutic use; D005221:Fatigue / Q000150:complications* / Q000188:drug therapy / Q000523:psychology*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D000077408:Modafinil; D009103:Multiple Sclerosis / Q000150:complications* / Q000523:psychology*; D011594:Psychometrics; D011788:Quality of Life
chemical_list: D001559:Benzhydryl Compounds; D000697:Central Nervous System Stimulants; D015259:Dopamine Agents; D000547:Amantadine; D000077408:Modafinil